In vitro effects of iron chelation of curcumin Fe (III) complex
Abstract
urpose: The aim of this study was to investigate the cytotoxicity effect, iron chelator and antioxidant activities of iron (III) ions with curcumin ligand that may be used in the treatment of iron overload.
Materials and Methods: The cytotoxic activities of the ligand and the complex were evaluated by the MTT assay. The SOD activity of the complex of curcumin was determined by using its ability to inhibit the reduction of NBT. The catalytic activity studies of Fe(III) complex in DMSO towards the disproportionation of hydrogen peroxide were also performed.
Results: The IC50 values are found in 6.8 μM catalase activity was measured. Where at a concentration of 2.0 mM, the activity was equivalent to 183.30 U/L. The complex shows a catalase activity. The complex showed minimal toxicity. IC50 values found 5.3 mg/ml. The observed cytotoxicity could be pursued to obtain a potential drug. The iron chelator effects were determined by Ferrozine reagent. Curcumin, the most active extract interfered with the formation of ferrous and ferrozine complex. It demonstrated strong chelating activities. The result showed that the complexes possess considerable SOD activity. This finding indicates that the iron complex is capable of removing free radicals.
Conclusion: The study results revealed that the iron(III) complex of curcumin with an appropriate potential drug may act as a protector against oxidative stress. Therefore, all results suggest that curcumin may represent a new approach in the treatment of iron overload.
Keywords
Kaynakça
- REFERENCES
- 1. Cairo G, F, Recalcati S. A precious metal: Iron, an essential nutrient for all cells. Genes & Nutrition, 2006, 1:25-39.
- 2. Kim A, Nemeth E, New insights into iron regulation and erythropoiesis. Curr Opin Hematol. 2015 22(3): 199–205.
- 3. Özbolat G, Yegani AA, Tuli A. Synthesis, characterization and electrochemistry studies of iron (iii) complex with curcumin ligand.2018; https://doi.org/10.1111/1440-1681.12964.
- 4. Siah CW, Ombiga J, Adams LA, Trinder D, Olynyk JK. Normal Iron Metabolism and the Pathophysiology of Iron Overload Disorders. Clin Biochem Rev. 2006; 27(1): 5–16.
- 5. Batt KP. Iron overload syndromes and the liver. Modern Pathology (2007) 20, S31–S39.
- 6. Lindsey WT, Bernie PD, Pharm RD. Deferasirox for Transfusion-Related Iron Overload: A Clinical Review. Clinical Therapeutics,2007; 29(10):2154-2166.
- 7. Özbolat G, Tuli A. Iron chelating ligand for iron overload diseases. Bratisl Med J. 2018; 119 (5) 308–311.
- 8. Shander A, Cappellini MD, Goodnough L. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang; 2009; 97:185–97.
- 9. Ehteram H, Bavarsad MS, Mokhtari M, et al. Prooxidant-antioxidant balance and hs-CRP in patients with beta-thalassemia major. Clin Lab. 2014; 60(2):207-15.
